2.Home care with acupuncture increased the quality of life in a patient with advanced cancer with neuropathic pain induced by bone metastasis: a case report.
Journal of Integrative Medicine 2018;16(3):208-210
A 66-year-old female patient was diagnosed with hepatocellular carcinoma accompanied by neuropathic pain induced by a metastatic tumor that compromised root and spinal canal. Although her pain was relieved following medical treatment, breakthrough pain occurring 1-2 times a day was still distressing. Neuropathic pain in her right lower limb caused discomfort and irritability and decreased her quality of life. We had limited options to adjust her prescription drug regime, due to the side effect of these drugs. Although acupuncture therapy was only performed at her home once a week, the efficacy was outstanding. The patient did not report any further instances of breakthrough pain, and she did not require additional bolus morphine. She could comfortably live in her familiar surroundings with her family and did not require any emergency room visits or admission into the hospital during the last month of her life. She had excellent quality of life in the terminal period of her life, and could even participate in a family function during this time. The present case report suggests that acupuncture may have a role in treating neuropathic pain induced by bone metastasis in patients with advanced cancer across clinical and in-home settings.
Acupuncture Therapy
;
Aged
;
Bone Neoplasms
;
complications
;
secondary
;
Carcinoma, Hepatocellular
;
pathology
;
Female
;
Home Care Services
;
Humans
;
Liver Neoplasms
;
pathology
;
Neoplasms
;
pathology
;
Neuralgia
;
etiology
;
therapy
;
Quality of Life
3.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Clinical and Molecular Hepatology 2015;21(2):115-121
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.
Carcinoma, Hepatocellular/complications/*pathology/therapy
;
Chemoembolization, Therapeutic
;
Combined Modality Therapy
;
Humans
;
Liver Neoplasms/complications/*pathology/therapy
;
Niacinamide/administration & dosage/analogs & derivatives
;
Phenylurea Compounds/administration & dosage
;
Portal Vein
;
Protein Kinase Inhibitors/administration & dosage
;
Venous Thrombosis/complications/*pathology
4.Curative effect of a comprehensive interventional treatment modality on hepatocellular carcinoma complicated with main branch portal vein tumor thrombosis.
Guo-bin XU ; Bin XIONG ; Qing-yun LONG
Chinese Journal of Hepatology 2013;21(5):367-371
OBJECTIVETo explore the therapeutic efficacy of a combined treatment modality using transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) to treat hepatocellular carcinoma (HCC) complicated with main branch intraportal vein tumor thrombosis (PVTT).
METHODSClinical data was collected retrospectively for patients diagnosed with and treated for HCC plus main branch PVTT at our hospital between January 2007 and January 2010. The total study population (n = 51) consisted of 38 males and 13 females, with an average of 50.1 years (range: 24-73). Among these patients, 26 had been treated with TACE + PEI (group A) and 25 had been treated with TACE alone (group B). Short-term changes in PVTT (i.e. disappearance, shrinkage, and/or stability) and tumor (i.e. complete response, partial response, and/or stable disease) were assessed by using the t-test (continuous variables) or the Chi-squared or Fisher's exact tests (categorical variables). Between-group differences in survival time were assessed by the Kaplan-Meier analysis and log-rank test.
RESULTSThe follow-up time ranged from 3-24 months after treatment, and no serious treatment-related complications were recorded for any of the patients (0/51). The time of TACE treatment was significantly longer for the patients receiving the combination therapy (group A: 3.21.4 vs. group B: 2.40.9, t = 2.22, P = 0.032). The patients in group A received between 2-8 PEI treatments. The TACE + PEI combined treatment showed significantly better therapeutic efficacy for PVTT (group A: 19/26 vs. group B: 10/25, X2 = 5.685, P = 0.019). The tumor response was significantly better in patients treated with TACE + PEI at post-treatment month 3 (group A: 20/26 vs. group B: 18/25, X2 = 0.163, P = 0.705) and month 6 (group A: 17/20 vs. 10/19, X2 = 2.58, P = 0.027). Finally, the average survival time was significantly better in patients treated with TACE + PEI (group A: 12.856.02 months (range: 5-23) vs. group B: 8.653.39 months (range: 4-16), t = 3.051, P = 0.004).
CONCLUSIONTACE + PEI combination therapy for main branch PVTT in HCC patients is more efficacious than TACE alone, and is associated with a longer survival time.
Adult ; Aged ; Carcinoma, Hepatocellular ; complications ; pathology ; therapy ; Chemoembolization, Therapeutic ; Combined Modality Therapy ; Ethanol ; administration & dosage ; Female ; Humans ; Injections, Subcutaneous ; Liver Neoplasms ; complications ; pathology ; therapy ; Male ; Middle Aged ; Neoplastic Cells, Circulating ; Portal Vein ; pathology ; Retrospective Studies ; Thrombosis ; complications
5.Treatment of hepatocellular carcinoma complicated with main portal vein tumor thrombus with transcatheter chemoembolization and portal vein stenting.
Xue-bin ZHANG ; Jian-hua WANG ; Zhi-ping YAN ; Sheng QIAN ; Gao-quan GONG ; Rong LIU ; Qing-xin LIU ; Jian-jun LUO ; Yi CHEN
Chinese Journal of Hepatology 2008;16(7):536-537
Carcinoma, Hepatocellular
;
complications
;
drug therapy
;
pathology
;
Chemoembolization, Therapeutic
;
methods
;
Female
;
Humans
;
Liver Neoplasms
;
complications
;
drug therapy
;
pathology
;
Male
;
Neoplastic Cells, Circulating
;
Portal Vein
;
pathology
;
Stents
;
Venous Thrombosis
;
complications
;
pathology
6.A case of advanced hepatocellular carcinoma with portal vein tumor invasion controlled by percutaneous ethanol injection therapy.
Ik YOON ; Hyung Joon YIM ; Jin Nam KIM ; Sun Min PARK ; Jeong Han KIM ; Seung Hwa LEE ; Hwan Hoon CHUNG ; Hong Sik LEE ; Sang Woo LEE ; Jai Hyun CHOI
The Korean Journal of Hepatology 2009;15(1):90-95
Portal vein invasion is a grave prognostic indicator in the setting of hepatocellular carcinoma (HCC). There is currently no effective method for preventing the invasion of HCC into the main portal vein. We report here a case of advanced HCC with portal vein tumor thrombosis that was effectively treated with percutaneous ethanol injection (PEI), having previously enabled subsequent successive transarterial chemoembolization (TACE). A 60-year-old male patient was diagnosed with a huge HCC, based on computed tomography and angiographic findings. Despite two sessions of TACE, the tumor invaded the right portal vein. PEI was performed on the malignant portal vein thrombosis, and three sessions thereof reduced the extent of tumor thrombi in the portal vein. Successive TACEs were performed to treat the HCC in the hepatic parenchyma. The patient was still living 19 months after the first PEI with no evidence of tumor recurrence, and his liver function remained well preserved.
Carcinoma, Hepatocellular/complications/*diagnosis/pathology
;
Chemoembolization, Therapeutic
;
Ethanol/*administration & dosage
;
Humans
;
Injections, Intralesional
;
Liver Neoplasms/complications/*diagnosis/pathology
;
Male
;
Middle Aged
;
Neoplasm Invasiveness
;
*Portal Vein/pathology
;
Tomography, X-Ray Computed
;
Venous Thrombosis/complications/diagnosis/*therapy
7.Hemothorax caused by spontaneous rupture of a metastatic mediastinal lymph node in hepatocellular carcinoma: a case report.
Ssang Yong OH ; Kwang Won SEO ; Yangjin JEGAL ; Jong Joon AHN ; Young Joo MIN ; Chang Ryul PARK ; Jae Cheol HWANG
The Korean Journal of Internal Medicine 2013;28(5):622-625
No abstract available.
Carcinoma, Hepatocellular/*complications/*secondary/therapy
;
Embolization, Therapeutic
;
Fatal Outcome
;
Hemothorax/diagnosis/*etiology/therapy
;
Humans
;
Liver Neoplasms/*complications/*pathology/therapy
;
Lymph Nodes/*pathology
;
Lymphatic Metastasis
;
Male
;
Mediastinum
;
Middle Aged
;
Paracentesis
;
Rupture, Spontaneous
;
Tomography, X-Ray Computed
;
Treatment Outcome
8.Managing non-alcoholic fatty liver disease.
Jing Hieng NGU ; George Boon Bee GOH ; Zhongxian POH ; Roy SOETIKNO
Singapore medical journal 2016;57(7):368-371
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly with the obesity and diabetes mellitus epidemics. It is rapidly becoming the most common cause of liver disease worldwide. NAFLD can progress to serious complications such as cirrhosis, hepatocellular carcinoma and death. Therefore, it is important to recognise this condition so that early intervention can be implemented. Lifestyle modifications and strict control of metabolic risk factors are the mainstay of treatment. As disease progression is slow in the majority of NAFLD patients, most can be managed well by primary care physicians. NAFLD patients with advanced liver fibrosis should be referred to specialist care for further assessment.
Carcinoma, Hepatocellular
;
pathology
;
Diet
;
Disease Progression
;
Humans
;
Life Style
;
Liver
;
pathology
;
Liver Cirrhosis
;
pathology
;
Liver Neoplasms
;
pathology
;
Metabolic Syndrome
;
complications
;
Non-alcoholic Fatty Liver Disease
;
diagnosis
;
therapy
;
Obesity
;
complications
;
Prevalence
;
Risk Factors
;
Treatment Outcome
9.Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings.
Joo Ho LEE ; Yung Sang LEE ; Pyo Nyun KIM ; Beom Hee LEE ; Gu Whan KIM ; Han Wook YOO ; Nae Yun HEO ; Young Suk LIM ; Han Chu LEE ; Young Hwa CHUNG ; Dong Jin SUH
The Korean Journal of Hepatology 2011;17(4):313-318
This is a case report of a 68-year-old man with hepatocellular carcinoma (HCC) accompanied by hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, and hepatic vascular malformation. HHT is an autosomal dominant disorder of the fibrovascular tissue that is characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations. HHT is caused by mutation of the genes involved in the signaling pathway of transforming growth factor-beta, which plays an important role in the formation of vascular endothelia1. Hepatic involvement has been reported as occurring in 30-73% of patients with HHT. However, symptomatic liver involvement is quite rare, and the representative clinical presentations of HHT in hepatic involvement are high-output heart failure, portal hypertension, nodular regenerative hyperplasia, and symptoms of biliary ischemia. Some cases of HCC in association with HHT have been reported, but are very rare. We present herein the characteristic radiologic and genetic findings of HHT that was diagnosed during the evaluation and treatment of HCC.
Activin Receptors, Type II/genetics
;
Aged
;
Angiography
;
Carcinoma, Hepatocellular/*complications/*therapy
;
Chemoembolization, Therapeutic
;
Exons
;
Gene Deletion
;
Humans
;
Liver Neoplasms/*complications/*therapy
;
Male
;
Mutation
;
*Telangiectasia, Hereditary Hemorrhagic/complications/genetics/pathology/radiography
;
Tomography, X-Ray Computed
10.A Case of Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases.
Jin Hee HONG ; Dong Dae SEO ; Tae Joo JEON ; Tae Hoon OH ; Won Chang SHIN ; Won Choong CHOI ; Hyun Sun CHO
The Korean Journal of Gastroenterology 2010;55(2):133-138
Spontaneous regression of hepatocellular carcinoma (HCC) is extremely rare. We report a case of 67-year-old man having HBV-associated HCC with multiple lung metastases which regressed spontaneously. The patient had single liver mass and received surgical resection. The mass was confirmed as HCC histopathologically. Nine years after surgical resection, a 3.3 cm sized recurred HCC was detected on the resection margin in CT scan. Transarterial chemoembolization (TACE) was performed 3 times, and lung metastases developed thereafter. The patient received 2 more sessions of TACE, however, metastatic lung nodules were in progress very rapidly. We decided to stop TACE and followed the patient regularly without any anti-cancer treatment. Nine months after development of lung metastasis, the size and number of metastatic lung nodules decreased and were not detected anymore after 14 months. Serum alpha-fetoprotein levels also decreased to normal range and no viable tumor was noted in the liver. The patient is still alive 12 years after the first diagnosis of HCC and 16 months after lung metastasis developed.
Aged
;
Carcinoma, Hepatocellular/*pathology/secondary/therapy
;
Chemoembolization, Therapeutic
;
Hepatitis B, Chronic/complications/diagnosis
;
Humans
;
Liver Neoplasms/complications/*pathology/therapy
;
Lung Neoplasms/*diagnosis/radiography/secondary
;
Male
;
Neoplasm Regression, Spontaneous
;
Neoplasm Staging
;
Tomography, X-Ray Computed
;
alpha-Fetoproteins/analysis